MeiraGTx Holdings (MGTX) Income from Continuing Operations (2017 - 2025)
MeiraGTx Holdings (MGTX) reported Income from Continuing Operations of 23695000.0 for Q4 2025, up 169.96% on a YoY basis from 8777202.49 in Q4 2024, and up 148.4% quarter-over-quarter from 48955000.0 in Q3 2025.
MeiraGTx Holdings (MGTX) Income from Continuing Operations (2017 - 2025) Analysis & Trends
MeiraGTx Holdings has reported Income from Continuing Operations for 9 years, with the latest figure at 23695000.0 in Q4 2025.
- For the quarter ending Q4 2025, Income from Continuing Operations rose 169.96% year-over-year to 23695000.0; the trailing twelve-month figure through Dec 2025 stood at 116347000.0 (up 32.88% YoY), and the FY2025 full-year result was 116347000.0, up 32.88% from the prior year.
- Income from Continuing Operations for Q4 2025 stood at 23695000.0, up from 48955000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 23695000.0 in Q4 2025, with the low at 48955000.0 in Q3 2025.
- Historically, Income from Continuing Operations has averaged 31553800.0 across 5 years, with a median of 34072000.0 in 2023.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations tumbled 459.0% — and 2025, when it surged 169.96%.
- MeiraGTx Holdings' Income from Continuing Operations stood at 7785000.0 in 2021, then plunged by 459.0% to 43518000.0 in 2022, then slipped by 7.21% to 46654000.0 in 2023, then rose by 27.4% to 33869000.0 in 2024, then soared by 169.96% to 23695000.0 in 2025.
- The last three Income from Continuing Operations figures came in at 23695000.0 (Q4 2025), 48955000.0 (Q3 2025), and 47419000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | MeiraGTx Holdings | 910.47 Mn | 844.54 Mn | 74.89 Mn | 23.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 23.70 Mn |
| Sep 30, 2025 | -48.96 Mn |
| Jun 30, 2025 | -47.42 Mn |
| Mar 31, 2025 | -43.67 Mn |
| Dec 31, 2024 | -33.87 Mn |
| Sep 30, 2024 | -42.21 Mn |
| Jun 30, 2024 | -48.34 Mn |
| Mar 31, 2024 | -48.93 Mn |
| Dec 31, 2023 | -46.65 Mn |
| Sep 30, 2023 | -35.62 Mn |
| Jun 30, 2023 | -31.49 Mn |
| Mar 31, 2023 | -34.28 Mn |
| Dec 31, 2022 | -43.52 Mn |
| Sep 30, 2022 | -24.41 Mn |
| Jun 30, 2022 | -23.80 Mn |
| Mar 31, 2022 | -28.80 Mn |
| Dec 31, 2021 | -7.79 Mn |
| Sep 30, 2021 | -22.58 Mn |
| Jun 30, 2021 | -20.47 Mn |
| Mar 31, 2021 | -22.00 Mn |